Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 6/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.53 |
| ▸ | EBP | Q15125 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | GUSB | P08236 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.45 |
| ▸ | DRD1 | P21728 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD5 | P21918 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130234 | 1.00 | GNAO1 (0.53) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| SCHEMBL14197717 | 1.00 | GNAO1 (0.53) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| SCHEMBL30375253 | 0.98 | GNAO1 (0.56) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| SCHEMBL15363082 | 0.98 | GNAO1 (0.56) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| SCHEMBL1071607 | 0.98 | GNAO1 (0.56) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| SCHEMBL8345209 | 0.98 | GNAO1 (0.56) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| Iodide SCHEMBL23004334 | 0.96 | GNAO1 (0.55) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| Hydrochloric Acid SCHEMBL23004272 | 0.96 | GNAO1 (0.59) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| Hydrochloric Acid SCHEMBL23004147 | 0.96 | GNAO1 (0.59) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| Bromide SCHEMBL23004426 | 0.96 | GNAO1 (0.55) | GNAO1GNAI3GNAI1EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330256-A1 | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2018-06-06 | — | — | EP | disclosed |
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | GNAO1 56/4885GNAI3 567/4885GNAI1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.